A novel polymorphism-driven transcriptional regulation of human glyoxalase 1 gene
| Project/Area Number |
16K19031
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
General medical chemistry
|
|---|
| Research Institution | Kanazawa University |
|---|
Principal Investigator |
Harashima Ai 金沢大学, 医学系, 助教 (50705522)
|
|---|
| Project Period (FY) |
2016-04-01 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2017: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2016: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Keywords | 転写調節 |
|---|
| Outline of Final Research Achievements |
Detoxifying enzyme glyoxalase 1 (GLO1) is known to be involved in the development of diabetes and its complications. However, the transcriptional regulation of GLO1 is not yet fully understood. In this study, we have identified novel polymorphisms in the human GLO1 promoter region. One of the polymorphisms was found to significantly upregulate the transcription of GLO1. We next addressed to reveal molecular mechanisms under the upregulation of the GLO1 transcription. As a result, the recruitment of histone proteins and the epigenetic modifications were involved in the transcriptional regulation. Cell culture conditions such as high glucose concentration or normoxia could change the frequency of the polymorphisms of the GLO1 gene. The polymorphisms were also found to link to the development of advanced diabetic vascular complications. These findings will offer a possible new avenue for the prevention and the treatment of GLO1-related diseases.
|
Report
(3 results)
Research Products
(19 results)
-
[Journal Article] In vitro anticancer effects of a RAGE inhibitor discovered using a structure-based drug design system.2018
Author(s)
El-Far A, Munesue S, Harashima A, Sato A, Shindo M, Nakajima S, Inada M, Tanaka M, Takeuchi A, Tsuchiya H, Yamamoto H, Shaheen HME, El-Sayed YS, Kawano S, Tanuma S, Yamamoto Y
-
Journal Title
Oncology Lett
Volume: 15
Pages: 4627-4634
NAID
Related Report
Peer Reviewed
-
[Journal Article] Anti-tumor effects of a non-steroidal anti-inflammatory drug zaltoprofen on chondrosarcoma via activating peroxisome proliferator-activated receptor gamma and suppressing matrix metalloproteinase-2 expression.2018
Author(s)
Higuchi T, Takeuchi, A, Munesue S, Yamamoto N, Hayashi K, Kimura H, Miwa S, Inatani H, Shimozaki S, Kato T, Aoki Y, Abe K, Taniguchi Y, Aiba H, Murakami H, Harashima A, Yamamoto Y, Tsuchiya H
-
Journal Title
Cancer Med
Volume: in press
NAID
Related Report
Open Access
-
-
[Journal Article] Intestinal transepithelial permeability of oxytocin into the blood is dependent on the receptor for advanced glycation end products in mice.2017
Author(s)
Higashida H, Furuhara K, Yamauchi AM, Deguchi K, Harashima A, Munesue S, Lopatina O, Gerasimenko M, Salmina AB, Zhang JS, Kodama H, Kuroda H, Tsuji C, Suto S, Yamamoto H, Yamamoto Y
-
Journal Title
Sci Rep
Volume: 11
Pages: 1-15
Related Report
Peer Reviewed / Open Access
-
[Journal Article] Low-dose paclitaxel suppresses the induction of M2 macrophages in gastric cancer.2017
Author(s)
Yamaguchi T, Fushida S, Yamamoto Y, Tsukada T, Kinoshita J, Oyama K, Miyashita T, Tajima H, Ninomiya I, Munesue S, Harashima A, Harada S, Yamamoto H and Ohta T.
-
Journal Title
Oncology Rep
Volume: in press
Related Report
Peer Reviewed
-
-
-
[Journal Article] Tumor-associated macrophages of the M2 phenotype contribute to progression in gastric cancer with peritoneal dissemination.2015
Author(s)
Yamaguchi T, Fushida S, Yamamoto Y, Tsukada T, Kinoshita J, Oyama K, Miyashita T, Tajima H, Ninomiya I, Munesue S, Harashima A, Harada S, Yamamoto H, Ohta T.
-
Journal Title
Gastric Cancer
Volume: 18
Issue: 4
Pages: 1-14
DOI
NAID
Related Report
Peer Reviewed / Open Access / Int'l Joint Research
-
-
-
-
-
-
-
-
-
-
-
